Stemcell Gains Rights to Geron’s IP Covering Stem Cells
Firm will use primate pluripotent SCs to develop media and matrices for research purposes.
Geron granted a nonexclusive license to Stemcell Technologies relating to primate pluripotent stem cells including human embryonic stem cells. Geron will receive license payments and is entitled to royalties on sales of products developed under the license.
Stemcell has the right to develop, manufacture, and sell cell culture media and matrix surfaces for research use only. The initial product under this deal is Stemcell’s mTeSR™1 medium, reportedly the first commercially available feeder-independent, serum-free, defined maintenance medium for human embryonic stem cells.
“Through our background in stem cell research and close ties with leading scientists we understand the ongoing technical challenges of performing cutting-edge research,” comments Terry Thomas, Ph.D., Stemcell’s vp of R&D. “Our goal is to provide innovative tools and reagents to meet these challenges and enable researchers to take their investigations to the next level. This agreement is a mechanism to supply researchers working with human embryonic stem cells with the tools they need.”